Hinova Pharmaceuticals Inc. (SHA:688302)

China flag China · Delayed Price · Currency is CNY
48.08
-1.01 (-2.06%)
At close: Jan 22, 2026
63.76%
Market Cap4.76B
Revenue (ttm)23.61M
Net Income (ttm)-144.57M
Shares Out99.02M
EPS (ttm)-1.45
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,364,218
Average Volume1,988,994
Open49.09
Previous Close49.09
Day's Range48.00 - 49.15
52-Week Range28.17 - 71.98
Beta0.01
RSI38.30
Earnings DateApr 25, 2026

About Hinova Pharmaceuticals

Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company’s products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501, a product in phase II clinical trials for the treatment of hyperuricemia and gout; HP558, a product in phase II clinical trials to treat various late... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 174
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688302
Full Company Profile

Financial Performance

Financial Statements